# Biotech Daily Digest â€” 2025-09-18

**38 items from 5 sources**

## Summary by Source

- Eli Lilly Press Releases: 1 item
- Endpoints News: 11 items
- Fierce Biotech: 6 items
- MHRA â€“ News: 1 item
- arXiv q-bio: 19 items


## Eli Lilly Press Releases

- **[Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes](https://investor.lilly.com/news-releases/news-release-details/lillys-mounjaro-tirzepatide-gipglp-1-dual-receptor-agonist)**  
  _Wed, 17 Sep 2025 18:01:00 -0400_  
  In SURPASS-PEDS, Mounjaro met the primary and all key secondary endpoints at 30 weeks and showed sustained improvement in glycemic control and continued BMI reduction through the study's 52-week extension Â The safety and tolerability profile of Mounjaro was generally consistent with previous adult


## Endpoints News

- **[Pfizer, Arvinas sell rights to lead PROTAC one month after filing for FDA review](https://endpoints.news/pfizer-arvinas-sell-rights-to-lead-protac-one-month-after-filing-for-fda-review/)**  
  _Thu, 18 Sep 2025 14:14:45 +0000_  
  Pfizer and Arvinas decided to out-license the lead program in their PROTAC collaboration after it fell short of expectations in late-stage clinical trials earlier this year.

 The companies said Wednesday that ...

- **[Shape Therapeutics strikes AAV capsid deal with VectorY worth up to $1.2B](https://endpoints.news/shape-therapeutics-strikes-aav-capsid-deal-with-vectory-worth-up-to-1-2b/)**  
  _Thu, 18 Sep 2025 13:45:49 +0000_  
  Shape Therapeutics has forged a major partnership months after letting go of a sizable portion of its workforce as it searches for a permanent CEO.

 The Seattle RNA gene therapy startup will team up with ...

- **[Leadership changes at Avid Bio and Charles River; Merck KGaA opens â‚¬150M Irish site](https://endpoints.news/leadership-changes-at-avid-bio-and-charles-river-merck-kgaa-opens-e150m-irish-site/)**  
  _Thu, 18 Sep 2025 13:30:05 +0000_  
  Welcome to Endpoints Newsâ€™ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more.

 Charles River Laboratories CFO Flavia Pease is stepping down after three years ...

- **[Acadia delays UK drug launch plans due to high market entry barrier for biotechs](https://endpoints.news/acadia-delays-uk-drug-launch-plans-due-to-high-market-entry-barrier-for-biotechs/)**  
  _Thu, 18 Sep 2025 12:40:30 +0000_  
  Acadia Pharmaceuticals' plans to seek UK approval for its Rett syndrome drug Daybue are "postponed indefinitely" due to high taxes and reimbursement challenges in the country, CEO Catherine Adams told Endpoints News in an interview ...

- **[A Blue Shield of California spinout aims to upgrade health plan's tech](https://endpoints.news/a-blue-shield-of-california-spinout-aims-to-upgrade-health-plans-tech/)**  
  _Thu, 18 Sep 2025 12:00:04 +0000_  
  Stellarus, a health tech spinout from Blue Shield of California, intends to deploy its technology that powers the insurer â€” starting with two other Blues plans.

 In January, Blue Shield of California restructured itself, creating a ...

- **[Roche to enter FGF21 space with $2.4B buyout of MASH biotech 89bio](https://endpoints.news/roche-to-enter-fgf21-space-via-2-4b-buyout-of-mash-biotech-89bio/)**  
  _Thu, 18 Sep 2025 11:02:16 +0000_  
  In its first acquisition of the year, Roche said it is spending $2.4 billion to buy 89bio and its late-stage candidate for fatty liver disease, marking the Swiss drugmakerâ€™s latest bid to boost its cardiometabolic ...

- **[#EASD25: Lilly seeks Mounjaro approval for children with diabetes following Phase 3 hit](https://endpoints.news/easd25-lilly-seeks-mounjaro-approval-for-children-with-diabetes-following-phase-3-hit/)**  
  _Thu, 18 Sep 2025 10:41:47 +0000_  
  VIENNA â€” Eli Lilly said Wednesday it had filed for approval of its diabetes drug Mounjaro in children after a Phase 3 trial showed that the shot cut blood sugar and body weight in patients as ...

- **[ArsenalBio, a well-funded cell therapy startup, halves workforce to focus resources](https://endpoints.news/arsenalbio-a-well-funded-cell-therapy-startup-halves-workforce-to-focus-resources/)**  
  _Thu, 18 Sep 2025 02:55:31 +0000_  
  Arsenal Biosciences is letting go of half of its staff, CEO Ken Drazan confirmed to Endpoints News.

 The major staffing cuts come almost a year to the day after the clinical-stage cell therapy maker  ...

- **[Federal Reserve cuts interest rates in modest win for biotech](https://endpoints.news/federal-reserve-cuts-interest-rates-in-modest-win-for-biotech/)**  
  _Wed, 17 Sep 2025 19:45:03 +0000_  
  The Federal Reserve on Wednesday cut interest rates by a quarter of a percentage point as expected, in a move that could breathe some life back into the biopharma industry.

 Biotechs and their investors have ...

- **[Regeneron heads to FDA with treatment for very rare bone disease](https://endpoints.news/regeneron-heads-to-fda-with-treatment-for-very-rare-bone-disease/)**  
  _Wed, 17 Sep 2025 19:31:06 +0000_  
  Regeneron reported that its experimental treatment substantially reduced harmful bone growths in people with a very rare disease, and itâ€™s planning to ask the FDA for approval.

 In fibrodysplasia ossificans progressiva ...

- **[X4 Pharmaceuticals restructures; Cytokinetics targets $650M raise](https://endpoints.news/x4-pharmaceuticals-restructures-cytokinetics-targets-650m-raise/)**  
  _Wed, 17 Sep 2025 14:42:49 +0000_  
  Plus, news about ARTHEx Biotech, Innate Pharma and AstraZeneca:

 ðŸ’¼ X4 Pharmaceuticals reveals changes: The biotech is letting go of 50% of its staff, including several executives. It had 143 employees ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/biogen-puts-its-back-85m-alcyone-buyout-securing-tech-spinal-drug-delivery" hreflang="en">Biogen strikes $85M Alcyone buyout, securing tech for spinal drug delivery </a>](https://www.fiercebiotech.com/biotech/biogen-puts-its-back-85m-alcyone-buyout-securing-tech-spinal-drug-delivery)**  
  _Sep 18, 2025 10:03am_  
  Biogen has given Alcyone Therapeutics a starring role in its drug delivery strategy, paying $85 million to buy the biotech and take control of an implant for getting medicines into the spinal canal.

- **[<a href="https://www.fiercebiotech.com/biotech/vectory-pens-12b-biobucks-pact-use-shapes-capsid-deliver-gene-therapies-brain" hreflang="en">VectorY pens $1.2B biobucks pact to use Shape's capsid to deliver gene therapies into brain</a>](https://www.fiercebiotech.com/biotech/vectory-pens-12b-biobucks-pact-use-shapes-capsid-deliver-gene-therapies-brain)**  
  _Sep 18, 2025 8:38am_  
  VectorY Therapeutics has seen the shape of things to comeâ€”and it involves finding fresh ways to deliver its gene therapies into the brain.

- **[<a href="https://www.fiercebiotech.com/biotech/pfizer-arvinas-lose-interest-commercializing-protac-inhibitor-leading-layoffs-biotech" hreflang="en">Pfizer, Arvinas lose interest in commercializing PROTAC inhibitor, leading to layoffs at the biotech</a>](https://www.fiercebiotech.com/biotech/pfizer-arvinas-lose-interest-commercializing-protac-inhibitor-leading-layoffs-biotech)**  
  _Sep 18, 2025 6:10am_  
  Having already stripped back their development plans for the estrogen receptor (ER) degrader vepdegestrant on the back of mixed data, Pfizer and Arvinas have decided to wash their hands of the drug.

- **[<a href="https://www.fiercebiotech.com/biotech/ql-biopharm-links-once-monthly-glp-1-incumbent-rivaling-weight-loss-phase-2" hreflang="en">QL Biopharm links once-monthly GLP-1 to incumbent-rivaling weight loss in phase 2</a>](https://www.fiercebiotech.com/biotech/ql-biopharm-links-once-monthly-glp-1-incumbent-rivaling-weight-loss-phase-2)**  
  _Sep 18, 2025 4:23am_  
  Beijing QL Biopharmaceutical has shared phase 2 data on its once-monthly GLP-1 candidate, providing early evidence that the ultra-long-acting prospect can match the efficacy of weekly products from Eli Lilly and Novo Nordisk.

- **[<a href="https://www.fiercebiotech.com/biotech/roche-becomes-mash-player-35b-deal-89bio-and-its-phase-3-drug" hreflang="en">Roche becomes MASH player via $3.5B deal for 89bio and its phase 3 drug</a>](https://www.fiercebiotech.com/biotech/roche-becomes-mash-player-35b-deal-89bio-and-its-phase-3-drug)**  
  _Sep 18, 2025 5:04am_  
  Roche dived into the metabolic dysfunction-associated steatohepatitis space by agreeing to hand over up to $3.5 billion for 89bio and its phase-3-stage candidate.

- **[<a href="https://www.fiercebiotech.com/biotech/arsenalbio-lays-50-staff-it-turns-away-early-stage-research" hreflang="en">ArsenalBio lays off 50% of staff in pivot from early-stage research</a>](https://www.fiercebiotech.com/biotech/arsenalbio-lays-50-staff-it-turns-away-early-stage-research)**  
  _Sep 17, 2025 4:57pm_  
  One of the top fundraisers of 2024 is halving its workforce about a year after bringing in a $325 million series C. Cell therapy biotech Arsenal Biosciences will lay off 50% of its staff as it restructures itself as a clinical-stage company, a spokesperson for the biotech has confirmed.


## MHRA â€“ News

- **[Transparency data: MHRA Performance Data](https://www.gov.uk/government/publications/mhra-performance-data)**  
  _2025-09-18T10:39:57Z_  
  Performance data for MHRA key performance indicators (KPIs) and information on the expected timeline to complete a specific regulatory function.


## arXiv q-bio

- **[Benchmarking Dimensionality Reduction Techniques for Spatial Transcriptomics](https://arxiv.org/abs/2509.13344)**  
  _Thu, 18 Sep 2025 00:00:00 -0400_  
  arXiv:2509.13344v1 Announce Type: new 
Abstract: We introduce a unified framework for evaluating dimensionality reduction techniques in spatial transcriptomics beyond standard PCA approaches. We benchmark six methods PCA, NMF, autoencoder, VAE, and two hybrid embeddings on a cholangiocarcinoma Xenium dataset, systematâ€¦

- **[Unleashing the power of computational insights in revealing the complexity of biological systems in the new era of spatial multi-omics](https://arxiv.org/abs/2509.13376)**  
  _Thu, 18 Sep 2025 00:00:00 -0400_  
  arXiv:2509.13376v1 Announce Type: new 
Abstract: Recent advances in spatial omics technologies have revolutionized our ability to study biological systems with unprecedented resolution. By preserving the spatial context of molecular measurements, these methods enable comprehensive mapping of cellular heterogeneity, tiâ€¦

- **[Why all roads don't lead to Rome: Representation geometry varies across the human visual cortical hierarchy](https://arxiv.org/abs/2509.13459)**  
  _Thu, 18 Sep 2025 00:00:00 -0400_  
  arXiv:2509.13459v1 Announce Type: new 
Abstract: Biological and artificial intelligence systems navigate the fundamental efficiency-robustness tradeoff for optimal encoding, i.e., they must efficiently encode numerous attributes of the input space while also being robust to noise. This challenge is particularly evidenâ€¦

- **[A Geometric Graph-Based Deep Learning Model for Drug-Target Affinity Prediction](https://arxiv.org/abs/2509.13476)**  
  _Thu, 18 Sep 2025 00:00:00 -0400_  
  arXiv:2509.13476v1 Announce Type: new 
Abstract: In structure-based drug design, accurately estimating the binding affinity between a candidate ligand and its protein receptor is a central challenge. Recent advances in artificial intelligence, particularly deep learning, have demonstrated superior performance over traâ€¦

- **[Complex-valued Phase Synchrony Reveals Directional Coupling in FMRI and Tracks Medication Effects](https://arxiv.org/abs/2509.13481)**  
  _Thu, 18 Sep 2025 00:00:00 -0400_  
  arXiv:2509.13481v1 Announce Type: new 
Abstract: Understanding interactions in complex systems requires capturing the directionality of coupling, not only its strength. Phase synchronization captures this timing, yet most methods either reduce phase to its cosine or collapse it into scaler indices such as phase-lockinâ€¦

- **[Rest2Visual: Predicting Visually Evoked fMRI from Resting-State Scans](https://arxiv.org/abs/2509.13612)**  
  _Thu, 18 Sep 2025 00:00:00 -0400_  
  arXiv:2509.13612v1 Announce Type: new 
Abstract: Understanding how spontaneous brain activity relates to stimulus-driven neural responses is a fundamental challenge in cognitive neuroscience. While task-based functional magnetic resonance imaging (fMRI) captures localized stimulus-evoked brain activation, its acquisitâ€¦

- **[Personalized Detection of Stress via hdrEEG: Linking Neuro-markers to Cortisol, HRV, and Self-Report](https://arxiv.org/abs/2509.13875)**  
  _Thu, 18 Sep 2025 00:00:00 -0400_  
  arXiv:2509.13875v1 Announce Type: new 
Abstract: Chronic stress is a major risk factor for cognitive decline, neurodegenerative disease, and systemic health burden, underscoring the need for reliable individual-level biomarkers of stress reactivity. While cortisol, heart rate variability (HRV), and self-report measureâ€¦

- **[Reaction-diffusion models of invasive tree pest spread: quantifying the spread of oak processionary moth in the UK](https://arxiv.org/abs/2509.14166)**  
  _Thu, 18 Sep 2025 00:00:00 -0400_  
  arXiv:2509.14166v1 Announce Type: new 
Abstract: UK woodlands, forests, and urban treescapes are under threat from invasive species, exacerbated by climate change, trade, and transport. Invasive tree pests debilitate their host and disrupt forest ecosystems, thus it is imperative to quantitatively model and predict thâ€¦

- **[PREDICT-GBM: Platform for Robust Evaluation and Development of Individualized Computational Tumor Models in Glioblastoma](https://arxiv.org/abs/2509.13360)**  
  _Thu, 18 Sep 2025 00:00:00 -0400_  
  arXiv:2509.13360v1 Announce Type: cross 
Abstract: Glioblastoma is the most prevalent primary brain malignancy, distinguished by its highly invasive behavior and exceptionally high rates of recurrence. Conventional radiation therapy, which employs uniform treatment margins, fails to account for patient-specific anatomâ€¦

- **[Generative AI Pipeline for Interactive Prompt-driven 2D-to-3D Vascular Reconstruction for Fontan Geometries from Contrast-Enhanced X-Ray Fluoroscopy Imaging](https://arxiv.org/abs/2509.13372)**  
  _Thu, 18 Sep 2025 00:00:00 -0400_  
  arXiv:2509.13372v1 Announce Type: cross 
Abstract: Fontan palliation for univentricular congenital heart disease progresses to hemodynamic failure with complex flow patterns poorly characterized by conventional 2D imaging. Current assessment relies on fluoroscopic angiography, providing limited 3D geometric informatioâ€¦

- **[Collective multicellular patterns arising from cadherin-linked cytoskeletal domains](https://arxiv.org/abs/2509.13556)**  
  _Thu, 18 Sep 2025 00:00:00 -0400_  
  arXiv:2509.13556v1 Announce Type: cross 
Abstract: In multicellular systems, adhesion complexes, such as those composed of E-cadherin and associated catenins, mechanically couple neighboring cells by directly linking their actin-based cytoskeletal assemblies. However, the mechanics of how forces are transmitted acrossâ€¦

- **[Plasticity-induced multistability on fast and slow timescales enables optimal information encoding and spontaneous sequence discrimination](https://arxiv.org/abs/2509.13867)**  
  _Thu, 18 Sep 2025 00:00:00 -0400_  
  arXiv:2509.13867v1 Announce Type: cross 
Abstract: Neural circuits exhibit remarkable computational flexibility, enabling adaptive responses to noisy and ever-changing environmental cues. A fundamental question in neuroscience concerns how a wide range of behaviors can emerge from a relatively limited set of underlyinâ€¦

- **[Multi-Source Neural Activity Indices and Spatial Filters for EEG/MEG Inverse Problem: An Extension to MNE-Python](https://arxiv.org/abs/2509.14118)**  
  _Thu, 18 Sep 2025 00:00:00 -0400_  
  arXiv:2509.14118v1 Announce Type: cross 
Abstract: Accurate EEG/MEG source localization is essential for understanding brain function, yet remains challenging because the inverse problem is inherently ill-posed. In spatial filtering (beamforming) approaches, single-source LCMV spatial filters, though widely used, suffâ€¦

- **[Deconstructing Intraocular Pressure: A Non-invasive Multi-Stage Probabilistic Inverse Framework](https://arxiv.org/abs/2509.14167)**  
  _Thu, 18 Sep 2025 00:00:00 -0400_  
  arXiv:2509.14167v1 Announce Type: cross 
Abstract: Many critical healthcare decisions are challenged by the inability to measure key underlying parameters. Glaucoma, a leading cause of irreversible blindness driven by elevated intraocular pressure (IOP), provides a stark example. The primary determinant of IOP, a tissâ€¦

- **[Language modulates vision: Evidence from neural networks and human brain-lesion models](https://arxiv.org/abs/2501.13628)**  
  _Thu, 18 Sep 2025 00:00:00 -0400_  
  arXiv:2501.13628v2 Announce Type: replace 
Abstract: Comparing information structures in between deep neural networks (DNNs) and the human brain has become a key method for exploring their similarities and differences. Recent research has shown better alignment of vision-language DNN models, such as CLIP, with the actâ€¦

- **[Maintaining diversity in structured populations](https://arxiv.org/abs/2503.09841)**  
  _Thu, 18 Sep 2025 00:00:00 -0400_  
  arXiv:2503.09841v2 Announce Type: replace 
Abstract: We examine population structures for their ability to maintain diversity in neutral evolution. We use the general framework of evolutionary graph theory and consider birth-death (bd) and death-birth (db) updating. The population is of size $N$. Initially all individâ€¦

- **[Predicting O-GlcNAcylation Sites in Mammalian Proteins with Transformers and RNNs Trained with a New Loss Function](https://arxiv.org/abs/2402.17131)**  
  _Thu, 18 Sep 2025 00:00:00 -0400_  
  arXiv:2402.17131v3 Announce Type: replace-cross 
Abstract: O-GlcNAcylation, a subtype of glycosylation, has the potential to be an important target for therapeutics, but methods to reliably predict O-GlcNAcylation sites had not been available until 2023; a 2021 review correctly noted that published models were insuffiâ€¦

- **[Emergence: from physics to biology, sociology, and computer science](https://arxiv.org/abs/2508.08548)**  
  _Thu, 18 Sep 2025 00:00:00 -0400_  
  arXiv:2508.08548v2 Announce Type: replace-cross 
Abstract: Many systems involve numerous interacting parts and the whole system can have properties that the individual parts do not. I take this novelty as the defining characteristic of an emergent property. Other characteristics associated with emergence discussed incâ€¦

- **[Excitonic Coupling and Photon Antibunching in Venus Yellow Fluorescent Protein Dimers: A Lindblad Master Equation Approach](https://arxiv.org/abs/2508.14233)**  
  _Thu, 18 Sep 2025 00:00:00 -0400_  
  arXiv:2508.14233v2 Announce Type: replace-cross 
Abstract: Strong excitonic coupling and photon antibunching (AB) have been observed together in Venus yellow fluorescent protein dimers and currently lack a cohesive theoretical explanation. In 2019, Kim et al. demonstrated Davydov splitting in circular dichroism spectrâ€¦
